Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 19/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.49 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3535302 | 0.88 | HDAC1 (0.61) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL3534436 | 0.78 | HDAC1 (0.64) | HDAC1HDAC2 | |
| SCHEMBL3539202 | 0.77 | HDAC1 (0.57) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL3534390 | 0.77 | HDAC1 (0.62) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL3539239 | 0.77 | HDAC1 (0.54) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL3535952 | 0.76 | HDAC1 (0.82) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL3538804 | 0.76 | HDAC1 (0.64) | HDAC1HDAC2HDAC6 | |
| SCHEMBL3540588 | 0.75 | HDAC1 (0.55) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL3532994 | 0.75 | HDAC1 (0.55) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL3535789 | 0.75 | HDAC1 (0.78) | HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642275-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-01-05 | — | — | US | claimed |
| EP-1824831-A2 | HISTONE DEACETYLASE INHIBITORS | Takeda San Diego, Inc. (US) | 2007-08-29 | — | — | EP | claimed |
| US-20060205941-A1 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. | 2006-09-14 | — | — | US | claimed |
| WO-2006066133-A2 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2006-06-22 | — | — | WO | claimed |
| US-7642275-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642275-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642275-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| EP-1824831-A2 | HISTONE DEACETYLASE INHIBITORS | Takeda San Diego, Inc. (US) | 2007-08-29 | — | — | EP | disclosed |
| US-20060205941-A1 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. | 2006-09-14 | — | — | US | disclosed |
| WO-2006066133-A2 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006066133-A2 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205941-A1 | Histone deacetylase inhibitors | HDAC1, HDAC3, HDAC5 | HDAC1 1/4885HDAC2 4/4885HDAC3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.